<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855268</url>
  </required_header>
  <id_info>
    <org_study_id>ACT16248</org_study_id>
    <secondary_id>2019-004394-10</secondary_id>
    <secondary_id>U1111-1223-4466</secondary_id>
    <secondary_id>RG012-03</secondary_id>
    <nct_id>NCT02855268</nct_id>
  </id_info>
  <brief_title>Study of SAR339375 in Patients With Alport Syndrome</brief_title>
  <acronym>HERA</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of SAR339375 for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

        -  To assess the efficacy of SAR339375 in reducing the decline in renal function

        -  To assess the safety and tolerability of SAR339375

      Secondary Objectives:

        -  To assess plasma pharmacokinetic (PK) parameters of the parent compound and its
           metabolites

        -  To assess the immunogenicity of the SAR339375
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The planned length of participation in the study for each subject is up to approximately 106
      weeks (from screening through completion of follow-up). This includes:

        -  Screening/baseline period of up to 4 weeks

        -  Double-blind, placebo-controlled treatment period of 48 weeks

        -  Open-label extension treatment period of 48 weeks ( opportunity for all subject to enter
           a 48-week open label extension period and receive active treatment with SAR339375)

        -  Post-treatment follow-up period of 6 weeks
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Baseline to maximum 102 weeks</time_frame>
    <description>Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized change in estimated glomerular filtration rate eGFR from baseline</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Annualized change in estimated glomerular filtration rate eGFR from baseline to 48 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) : Maximum concentration in plasma (Cmax)</measure>
    <time_frame>24 weeks and 48 weeks</time_frame>
    <description>Plasma concentrations (Cmax) of parent SAR339375 and its metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) : Trough plasma concentration (Ctrough)</measure>
    <time_frame>24 weeks and 48 weeks</time_frame>
    <description>Plasma concentrations (Ctrough) of parent SAR339375 and its metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-drug antibodies (ADAs)</measure>
    <time_frame>Baseline to maximum 102 weeks</time_frame>
    <description>Number of participants with ADAs incidents and titer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participant with adverse events associated to ADAs</measure>
    <time_frame>Baseline to maximum 102 weeks</time_frame>
    <description>Association of ADAs with adverse events per participants will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in eGFR values</measure>
    <time_frame>Baseline to 24 weeks and 48 weeks</time_frame>
    <description>Percent change in eGFR values from baseline to 24 weeks and 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who reach end staged renal disease (ESRD)</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Proportion of participants who reach ESRD as defined by an eGFR ≤15 mL/min/1.73 m^2 or initiation of hemodialysis or renal transplantation from baseline to 48 weeks -</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Alport's Syndrome</condition>
  <arm_group>
    <arm_group_label>Lademirsen (SAR339375)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will receive subcutaneous injection every week for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible participants will receive subcutaneous injection every week for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lademirsen (SAR339375)</intervention_name>
    <description>Pharmaceutical form:Solution for injection Route of administration: Subcutaneous injection</description>
    <arm_group_label>Lademirsen (SAR339375)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form:Solution for injection Route of administration: Subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Male or female

          -  Confirmed diagnosis of Alport syndrome

               1. Clinical diagnosis (hematuria, family history, hearing loss, ocular change), AND

               2. Genetic confirmation of Alport Syndrome in the subject or the family member, OR

               3. Kidney biopsy showing glomerular basement membrane abnormalities (eg, significant
                  thinning, thickening, irregularity or lucencies) consistent with Alport Syndrome.

          -  Age 18-55 years old

          -  eGFR &gt; 35 ml/min/1.73m^2 and &lt;90 mL/min/1.73m^2 (based on CKD-EPI) at screening

          -  Renal Function Criteria (patients must meet at least one of the following CRITERIA A,
             B or C):

          -  A)Decline in eGFR of ≥4 mL/min/1.73 m^2/year (eGFR slope &lt;= -4) based on a linear
             regression slope analysis of ≥4 eGFR measurements within 3 years prior to the study
             and with a minimum of 2-year time span (the last, of the screening measurement, and
             first eGFR measurements should be separated by at least 2 years). eGFR should be
             calculated by using either the Chronic Kidney Disease Epidemiology Collaboration
             (CKD-EPI) creatinine equation.

          -  B) proteinuria (UPCR) &gt;2000 mg/g (UACR&gt;1000 mg/g)

          -  C) Age and sex adjusted eGFR (based on CKD-Epi; male 18-23 eGFR&lt;90 mL/min/1.73m^2

          -  ACE inhibitor and/or ARB, the dosing regimen should be stable for at least 30 days
             prior to screening

          -  Sexually active female subjects of childbearing potential and sexually mature male
             subjects must agree to practice true abstinence in line with their preferred and usual
             lifestyle or to use two acceptable effective methods of contraception for the entire
             duration of the study and for at least 6 weeks after last dose.

          -  Negative drug screen for opiates, cocaine, heroin, phencyclidine, amphetamines
             (including ecstasy), barbiturates, benzodiazepines, and cannabinoids. At the
             Investigator's discretion, subjects prescribed benzodiazepines, cannabinoids, or
             opiates with positive results on a drug screen may be allowed.

          -  Negative screening results for hepatitis B surface antigen (HBsAg), hepatitis C virus
             (HCV) antibody, and human immunodeficiency virus (HIV) antibody

          -  Normal biological tests

          -  Able to understand all study procedures in the informed consent form (ICF) and willing
             to comply with all aspects of the protocol

        Exclusion criteria:

          -  Causes of chronic kidney disease aside from Alport syndrome (including but not limited
             to other heritable disorders leading to chronic kidney disease, diabetic nephropathy,
             hypertensive nephropathy, lupus nephritis, IgA nephropathy)

          -  ESRD as evidenced by ongoing dialysis therapy or history of renal transplantation

          -  Any clinically significant illness within 30 days before screening or surgical or
             medical condition (other than Alport syndrome) that could interfere with the subject's
             study compliance; confound the study results; impact subject safety; or significantly
             alter the absorption, distribution, metabolism, or excretion of drugs.

          -  Weight &gt; 110 kg

          -  Any history of active malignancy within the last 1 year (history of localized basal
             cell or squamous cell carcinoma and cervical carcinoma in situ that has been
             excised/appropriately treated or a fully excised malignant lesion with a low
             probability of recurrence will not be considered exclusionary)

          -  Prior treatment with Bardoxolone within 90 days prior to screening

          -  History or presence of alcoholism or drug abuse within 2 years before screening or
             other concurrent social conditions that would potentially interfere with the subject's
             study compliance, at the discretion of the Investigator

          -  Participation in a recent investigational study and receipt of an investigational drug
             or investigational use of a licensed drug within 30 days or 5 half lives, whichever is
             longer, prior to screening

          -  History or presence of hypersensitivity or idiosyncratic, allergic, or other
             clinically significant reaction to the study drug (including placebo), inactive
             ingredients, or related compounds (eg, other oligonucleotide products)

          -  Any other condition or circumstance that, in the opinion of the Investigator, may make
             the subject unlikely to complete the study or comply with study procedures and
             requirements, or may pose a risk to the subject's safety and well-being

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360003</name>
      <address>
        <city>Herston</city>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0360001</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500002</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8260002</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney disease</keyword>
  <keyword>Nephritis</keyword>
  <keyword>Hereditary nephritis</keyword>
  <keyword>Hereditary kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis, Hereditary</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

